Category: Drug Discovery
Drug Discovery market research reports by DelveInsight
-
Chronic Kidney Disease - Pipeline Insight, 2024
Chronic Kidney Disease - Pipeline Insight, 2024 DelveInsight’s, “Chronic Kidney Disease - Pipeline Insight, 2024” report provides comprehensive insights about 76+ companies and 80+ pipeline drugs in Chronic Kidney Disease pipeline landscape. It covers the pipeline drug profiles, including clinical a ... Read More
-
Dystrophic Epidermolysis Bullosa - Pipeline Insight, 2024
Dystrophic Epidermolysis Bullosa - Pipeline Insight, 2024 DelveInsight’s, “Dystrophic Epidermolysis Bullosa - Pipeline Insight, 2024,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Dystrophic Epidermolysis Bullosa pipeline landscape. It covers the pipeline drug ... Read More
-
Idiopathic Pulmonary Fibrosis - Pipeline Insight, 2024
Idiopathic Pulmonary Fibrosis - Pipeline Insight, 2024 DelveInsight’s, “Idiopathic Pulmonary Fibrosis - Pipeline Insight, 2024” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Idiopathic Pulmonary Fibrosis pipeline landscape. It covers the pipeline drug profiles ... Read More
-
Glaucoma - Pipeline Insight, 2024
Glaucoma - Pipeline Insight, 2024 DelveInsight’s, “Glaucoma Disease- Pipeline Insight, 2024” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Glaucoma Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage prod ... Read More
-
Turner Syndrome - Pipeline Insight, 2024
Turner Syndrome - Pipeline Insight, 2024 DelveInsight’s, “Turner Syndrome - Pipeline Insight, 2024” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Turner Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage pr ... Read More
-
Type 1 fibroblast growth factor receptor antagonists - Pipeline Insight, 2024
Type 1 fibroblast growth factor receptor antagonists - Pipeline Insight, 2024 DelveInsight’s, “Type 1 Fibroblast Growth Factor Receptor Antagonists - Pipeline Insight, 2024” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Type 1 Fibroblast Growth Factor Receptor ... Read More
-
Tuberculosis - Pipeline Insight, 2024
Tuberculosis - Pipeline Insight, 2024 DelveInsight’s, “Tuberculosis – Pipeline Insight, 2024,” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Tuberculosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products ... Read More
-
Gonadotropin-Releasing Hormone (GnRH) Receptor (LHRH Receptor) Antagonist - Pipeline Insight, 2024
Gonadotropin-Releasing Hormone (GnRH) Receptor (LHRH Receptor) Antagonist - Pipeline Insight, 2024 “Gonadotropin-Releasing Hormone (GnRH) Receptor (LHRH Receptor) Antagonist - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutic ... Read More
-
Multiple sclerosis - Pipeline Insight, 2024
Multiple sclerosis - Pipeline Insight, 2024 DelveInsight’s, “Multiple sclerosis - Pipeline Insight, 2024,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Multiple sclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and noncli ... Read More
-
Tuberous Sclerosis- Pipeline Insight, 2024
Tuberous Sclerosis- Pipeline Insight, 2024 DelveInsight’s, “Tuberous Sclerosis- Pipeline Insight, 2024” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Tuberous Sclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinica ... Read More
-
Selective COX-2 Inhibitor - Pipeline Insight, 2024
Selective COX-2 Inhibitor - Pipeline Insight, 2024 “Selective COX-2 Inhibitor - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Selective COX-2 Inhibitor development. The report provide ... Read More
-
Sensory Neuropathy - Pipeline Insight, 2024
Sensory Neuropathy - Pipeline Insight, 2024 Sensory Neuropathy Overview ""Sensory Neuropathy Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Sensory Neuropathy market. A detailed picture of the Se ... Read More
-
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Insight, 2024
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Insight, 2024 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Overview ""Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insig ... Read More
-
Severe Keratitis - Pipeline Insight, 2024
Severe Keratitis - Pipeline Insight, 2024 Severe Keratitis Overview ""Severe Keratitis Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Severe Keratitis market. A detailed picture of the Severe Ker ... Read More
-
Interleukin-2 (IL-2) Inhibitor - Pipeline Insight, 2024
Interleukin-2 (IL-2) Inhibitor - Pipeline Insight, 2024 DelveInsight’s, “Interleukin-2 (IL-2) Inhibitor - Pipeline Insight, 2024” report provides comprehensive insights about 8+ companies and 10 pipeline drugs in Interleukin-2 (IL-2) Inhibitor pipeline landscape. It covers the pipeline drug profile ... Read More
-
Cutaneous Lupus Erythematosus – Pipeline Insight, 2024
Cutaneous Lupus Erythematosus – Pipeline Insight, 2024 DelveInsight’s, “Cutaneous Lupus Erythematosus – Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Cutaneous Lupus Erythematosus pipeline landscape. It covers the pipeline drug profiles ... Read More
-
11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitor - Pipeline Insight, 2024
11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitor - Pipeline Insight, 2024 “11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitor - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growt ... Read More
-
Complicated skin and soft tissue infections (cSSTI) - Pipeline Insight, 2024
Complicated skin and soft tissue infections (cSSTI) - Pipeline Insight, 2024 DelveInsight’s, “Complicated Skin and Soft Tissue Infections (cSSTI) - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Complicated Skin and Soft Tissue Infections ... Read More
-
Uremic Pruritus and Associated Dry Skin - Pipeline Insight, 2024
Uremic Pruritus and Associated Dry Skin - Pipeline Insight, 2024 Uremic Pruritus and Associated Dry Skin Overview ""Uremic Pruritus and Associated Dry Skin Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects acr ... Read More
-
22q11.2 Deletion Syndrome - Pipeline Insight, 2024
22q11.2 Deletion Syndrome - Pipeline Insight, 2024 22q11.2 Deletion Syndrome Overview ""22q11.2 Deletion Syndrome Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the 22q11.2 Deletion Syndrome market. ... Read More
-
Undifferentiated Pleomorphic Sarcoma (UPS) - Pipeline Insight, 2024
Undifferentiated Pleomorphic Sarcoma (UPS) - Pipeline Insight, 2024 Undifferentiated Pleomorphic Sarcoma (UPS) Overview ""Undifferentiated Pleomorphic Sarcoma (UPS) Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth pros ... Read More
-
5-HT1B Antagonist - Pipeline Insight, 2024
5-HT1B Antagonist - Pipeline Insight, 2024 “5-HT1B Antagonist - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across 5-HT1B Antagonist development. The report provides detailed coverage of t ... Read More
-
Toll-Like Receptor Agonist - Pipeline Insight, 2024
Toll-Like Receptor Agonist - Pipeline Insight, 2024 “Toll-Like Receptor Agonist - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Toll-Like Receptor Agonist development. The report prov ... Read More
-
Transient Receptor Potential Vanilloid 1 (TRPV-1) Receptor (Capsaicin Receptor or Vanilloid Receptor 1) Agonist - Pipeline Insight, 2024
Transient Receptor Potential Vanilloid 1 (TRPV-1) Receptor (Capsaicin Receptor or Vanilloid Receptor 1) Agonist - Pipeline Insight, 2024 “Transient Receptor Potential Vanilloid 1 (TRPV-1) Receptor (Capsaicin Receptor or Vanilloid Receptor 1) Agonist - Pipeline Insight, 2024” report by DelveInsight o ... Read More
-
TGF-Beta-1 Inhibitor - Pipeline Insight, 2024
TGF-Beta-1 Inhibitor - Pipeline Insight, 2024 “TGF-Beta-1 Inhibitor - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across TGF-Beta-1 Inhibitor development. The report provides detailed cove ... Read More